Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Mandel

Showing results (1-10 of 219) with videos related to

Pageof 22
Sort By:
The Journal of Urology|July 23, 2021
Editorial CommentFelix Preisser, Philipp Mandel
European Urology|July 16, 2017
Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50Philipp Mandel, Derya Tilki
Current Opinion in Urology|August 22, 2017
Radical prostatectomy in oligometastatic prostate cancerPhilipp Mandel, Thomas Steuber, Markus Graefen
Urologic Oncology|July 17, 2014
Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysisPhilipp Mandel, Derya Tilki, Guy D Eslick
Central European Journal of Urology|February 9, 2016
SUPRAPUR(®): Safe and convenient percutaneous suprapubic catheterisation in high-risk patientsMaximilian Christian Kriegmair, Philipp Mandel, Manuel Ritter
European Urology|July 18, 2017
Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?Philipp Mandel, Markus Graefen, Hartwig Huland, et al.
Chinese Clinical Oncology|October 11, 2023
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?Benedikt Hoeh, Felix K H Chun, Philipp Mandel
European Urology Focus|February 22, 2023
Reply to Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, et al's Letter to the Editor re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007Benedikt Hoeh, Felix K H Chun, Philipp Mandel
European Urology Open Science|October 6, 2022
Diagnosis of Clinically Significant Prostate Cancer Diagnosis Without Histological Proof in the Prostate-specific Membrane Antigen Era: The Jury Is Still OutMike Wenzel, Benedikt Hoeh, Philipp Mandel, et al.
Plos One|January 1, 2015
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptorsSusanne Brand, Kerstin Amann, Philipp Mandel, et al.
Pageof 22

Showing results (1-10 of 219) with videos related to

Sort By:
Pageof 22
The Journal of Urology|July 23, 2021
Editorial CommentFelix Preisser, Philipp Mandel
European Urology|July 16, 2017
Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50Philipp Mandel, Derya Tilki
Current Opinion in Urology|August 22, 2017
Radical prostatectomy in oligometastatic prostate cancerPhilipp Mandel, Thomas Steuber, Markus Graefen
Urologic Oncology|July 17, 2014
Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysisPhilipp Mandel, Derya Tilki, Guy D Eslick
Central European Journal of Urology|February 9, 2016
SUPRAPUR(®): Safe and convenient percutaneous suprapubic catheterisation in high-risk patientsMaximilian Christian Kriegmair, Philipp Mandel, Manuel Ritter
European Urology|July 18, 2017
Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?Philipp Mandel, Markus Graefen, Hartwig Huland, et al.
Chinese Clinical Oncology|October 11, 2023
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?Benedikt Hoeh, Felix K H Chun, Philipp Mandel
European Urology Focus|February 22, 2023
Reply to Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, et al's Letter to the Editor re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007Benedikt Hoeh, Felix K H Chun, Philipp Mandel
European Urology Open Science|October 6, 2022
Diagnosis of Clinically Significant Prostate Cancer Diagnosis Without Histological Proof in the Prostate-specific Membrane Antigen Era: The Jury Is Still OutMike Wenzel, Benedikt Hoeh, Philipp Mandel, et al.
Plos One|January 1, 2015
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptorsSusanne Brand, Kerstin Amann, Philipp Mandel, et al.
Pageof 22